Atara Biotherapeutics, Inc.
ATRA
NASDAQ·Healthcare·Biotechnology·Mkt cap $87.9M
$9.76
▲ +2.41%
P/E
-8.27
Mkt Cap
$87.9M
52-Wk Range
$3.92–$19.15
52-Week Range
$3.92 - $19.15
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 19.9% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Off-the-shelf T-cell immunotherapy reducing manufacturing complexity and costs
- Strong clinical validation with Phase 3 trials and institutional partnerships
- Diverse pipeline addressing multiple cancer types and autoimmune diseases
- Strategic collaborations with Bayer AG, Memorial Sloan Kettering, and leading research institutions
Bear Case
1 risk
- Low volatility (beta 0.1).
Growth
Revenue decline expected
Phase 3 clinical trial success and regulatory approvals for tabelecleucel
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Stable
+1.9% over 3m
Quality
Excellent
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying ATRA right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Oct 29, 2026
AUG 11, 2026
Reported EPS of -$0.32 vs -$0.32 consensus (-1.6% surprise). Revenue of $630.0K vs $550.0K expected (+14.6%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-1.6%
Revenue trend · last 8Q
—
—
+259%
-39%
-91%
-95%
-100%
-103%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$40.2M
$32.8M
$98.1M
$17.6M
$3.5M
$1.6M
$0
-$516.0K
Margins · last 8Q
Gross
—
Operating
—
Profit
—
Wall Street consensus
2 analysts · 50% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
50%
Hold
50%
Sell
0%
Median Price Target
—
Latest: Freedom Broker · May 18, 2026
vs Industry
How ATRA stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related